Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Business meeting

The ten-year, multi-million-pound fund will support social ventures created within the participating universities across the UK. The fund will support ventures motivated by beneficial social or environmental impact, rather than solely by profit.

Impact 12 has been developed by Social Investment Scotland (SIS), an impact investor and responsible finance provider based in Edinburgh, in partnership with the Universities of Oxford, Cambridge, Northampton, Coventry and eight universities comprising the MICRA Project (Aston, Birmingham, Cranfield, Keele, Leicester, Loughborough, Nottingham and Warwick). Oxford University Innovation leads the consortium.

Impact 12’s aim is to bring positive change, to people and places, by accelerating the development and success of impact-led social ventures spun out of universities. It will support social ventures with innovative finance tailored to their needs, including equity investment and debt. The fund will also provide access to timely and expert mission-aligned finance and impact support.

Read the full story on the Oxford University Innovation website

The story is also featured on the University of Oxford website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.